Zelnorm
(Tegaserod)ApprovedSmall molecule
Tegaserod is used to treat irritable bowel syndrome with constipation and chronic constipation by helping the colon muscles contract and move stool more regularly.[2] Zelnorm is currently approved and in use across 6 indications[4].[1]
Zelnorm is one of 158 small molecule programs targeting Gastroparesis. It is currently in Approved.
6
Indications
23
Total Trials
0
Active Trials
157
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
185 competitors in Irritable Bowel Syndrome
#DrugCompanyPhaseTrials
1Zelnorm
AAlfasigma S.p.A.
Approved
Lialda
TakedaPhase 3
Xifaxan
SSalix
Phase 3
Zofran
NovartisPhase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Zarontin
PParkedale
Phase 3
Mesalazine
FerringPhase 3
Saccharomyces Boulardii
BBiocodex
Phase 3
Trulance
SSalix
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic constipation5 trials
Dyspepsia5 trials
Constipation3 trials
Irritable Bowel Syndrome3 trials
Gastroesophageal Reflux Disease3 trials
4 more indications
ESS1 trial
Treatment1 trial
Regulatory
FDA Approval Timeline[5]
Jul 24, 2002
ZELNORM
NDA NDA021200
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Zelnorm drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tegaserod. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serotonin 4 (5-HT4) Receptor Partial Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAlfasigma S.p.A.